证券代码：002252 证券简称：上海莱士 上海莱士血液制品股份有限公司 投资者关系活动记录表 编号：2023-010 √特定对象调研 □分析师会议 投资者关系 □媒体采访 □业绩说明会 活动类别 □新闻发布会 □路演活动 □现场参观 □其他（请文字说明其他活动内容） 参与单位名称 Cobas Asset Management 詹明昆 及人员姓名 时间 2023年 11月3日 14:00—15:30 地点 公司会议室 上市公司 刘 峥 副总经理、董事会秘书 接待人员姓名 陈乐奇 财务负责人 褚忠君 市场总监 一、公司介绍 1、财务负责人就公司财务情况作简要介绍； 2、市场总监就血液制品市场情况作简要介绍。 ...

证券代码：002252 证券简称：上海莱士 上海莱士血液制品股份有限公司 投资者关系活动记录表 编号：2023-009 √特定对象调研 □分析师会议 投资者关系 □媒体采访 □业绩说明会 活动类别 □新闻发布会 □路演活动 □现场参观 □其他（请文字说明其他活动内容） 参与单位名称 GL Capital Group朱柏力 及人员姓名 GL Capital Group邹悦 时间 2023年 11月1日 14:00—16:00 地点 公司会议室 上市公司 刘 峥 副总经理、董事会秘书 接待人员姓名 一、交流互动环节 问题 1：请介绍下公司产品结构的趋势？ 回复：血液制品企业以生产人血白蛋白类、静注人免疫球蛋白类为 主， 上述两类产品处于供需紧平衡状态。目前，凝血因子类产品的市场需求具有 ...

Financial Performance - The company's revenue for Q3 2023 reached ¥2,034,744,817.97, representing a 22.72% increase compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2023 was ¥548,605,548.04, a slight increase of 1.08% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥603,604,791.17, up 11.36% from the previous year[3]. - Total operating revenue for the current period reached ¥5,935,370,613.02, a 19.9% increase from ¥4,951,543,979.15 in the previous period[25]. - Net profit for the current period was ¥1,785,618,617.73, representing a 11.6% increase compared to ¥1,599,553,187.66 in the previous period[26]. - Total comprehensive income for the current period was ¥2,242,597,415.86, down from ¥3,068,200,086.26 in the previous period[26]. Assets and Liabilities - The total assets at the end of Q3 2023 amounted to ¥31,912,459,945.21, reflecting a 4.78% increase from the end of the previous year[3]. - As of September 30, 2023, total assets amounted to approximately 31.91 billion yuan, an increase from 30.46 billion yuan at the beginning of the year[22]. - The total liabilities as of September 30, 2023, were approximately 2.09 billion yuan, compared to 1.64 billion yuan at the beginning of the year[23]. - The company's total equity increased to approximately 29.82 billion yuan as of September 30, 2023, from 28.81 billion yuan at the beginning of the year[23]. Cash Flow - The company's cash flow from operating activities for the year-to-date reached ¥1,940,451,824.32, a significant increase of 61.25% compared to the same period last year[7]. - Operating cash flow net amount was ¥1,940,451,824.32, an increase of 61.4% from ¥1,203,356,366.64 in the previous period[29]. - Cash and cash equivalents at the end of the period totaled ¥3,580,923,338.88, up from ¥2,243,907,832.11 at the end of the previous period[29]. - The company's cash and cash equivalents stood at approximately 4.02 billion yuan as of September 30, 2023, up from 3.98 billion yuan at the beginning of the year[21]. Shareholder Information - As of September 28, 2023, the total number of common shareholders is 103,398[9]. - GRIFOLS, S.A. holds 26.20% of shares, totaling 1,766,165,808 shares, making it the largest shareholder[9]. - The top ten shareholders include several state-owned and foreign entities, with significant stakes held by China Cinda Asset Management Co., Ltd. (4.14%) and China Huarong Asset Management Co., Ltd. (3.65%)[9]. - The company confirmed that there are no related party transactions among the top ten shareholders, except for certain relationships within the CITIC Group[10]. Share Repurchase Plan - The company has implemented a share buyback plan, resulting in a net cash outflow of ¥1,088,886,701.78 from financing activities[7]. - The company has repurchased a total of 136,153,070 shares, representing 2.0198% of the total share capital, with a total expenditure of approximately RMB 999.69 million[15]. - The highest repurchase price was RMB 7.56 per share, while the lowest was RMB 7.06 per share[15]. - The repurchase plan was approved with a total budget of between RMB 500 million and RMB 1 billion, with a maximum price of RMB 8.00 per share[12]. - The first repurchase occurred on July 14, 2023, with 6,531,878 shares bought back at a total cost of approximately RMB 48.78 million[13]. - The company has disclosed the progress of the share repurchase on multiple occasions, including on August 3, 5, and 21, 2023[14]. - The repurchase plan is set to be completed within 12 months from the approval date, contingent on specific conditions being met[12]. Employee Stock Ownership Plan (ESOP) - The employee stock ownership plan (ESOP) aims to use up to 33.77 million repurchased shares, accounting for approximately 0.50% of the total share capital of 674.08 million shares[16]. - The total amount of funds raised through the ESOP is expected to be no more than 121.91 million yuan, with actual subscription funds amounting to 113.17 million yuan as of September 25, 2023[16]. - The company has completed the non-trading transfer of 31.35 million shares to the ESOP account at a transfer price of 3.61 yuan per share, representing 0.47% of the total share capital[17]. Operational Metrics - The gross profit margin decreased due to an increase in the sales proportion of imported albumin, which has a lower gross margin compared to self-produced products[7]. - The company reported a 19.87% increase in total revenue for the year-to-date, driven primarily by growth in imported albumin and immunoglobulin sales[6]. - The company experienced a 38.42% increase in accounts payable, mainly due to increased payables from agency import business[6]. - The company reported a decrease in contract liabilities by 88.63%, indicating a reduction in advance payments received[6]. - The company reported a decrease in accounts receivable from approximately 707.02 million yuan to 654.86 million yuan during the same period[21]. - The company’s inventory increased from approximately 3.27 billion yuan to 3.37 billion yuan as of September 30, 2023[21]. - Research and development expenses for the current period were ¥132,454,755.35, a 29.7% increase from ¥102,089,434.95 in the previous period[25].

证券代码：002252 证券简称：上海莱士 公告编号：2023-070 上海莱士血液制品股份有限公司 关于第五届董事会第二十八次（临时）会议决议公告 上海莱士血液制品股份有限公司（"公司"）第五届董事会第二十八次（临时） 会议于 2023 年 10 月 18 日以电话和邮件方式发出会议通知，并于 2023 年 10 月 23 日下午 3 点以通讯方式召开。 本次会议应出席董事 9 名，实际出席会议董事 9 名。本次会议由公司董事长、 总经理 Jun Xu（徐俊）先生主持。会议的召集、召开与表决程序符合《公司法》 和《公司章程》等有关规定。会议在保证所有董事充分发表意见的前提下，全体 与会董事经投票表决，一致作出如下决议： 1、审议通过《2023 年第三季度报告》 表决结果：9票同意、0票反对、0票弃权。 《2023年第三季度报告》刊登于《证券时报》、《中国证券报》、《上海证券报》、 《证券日报》和巨潮资讯网（www.cninfo.com.cn），供投资者查阅。 特此公告。 上海莱士血液制品股份有限公司 董事会 二〇二三年十月二十五日 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载 ...

证券代码：002252 证券简称：上海莱士 公告编号：2023-069 上海莱士血液制品股份有限公司 第一期员工持股计划第一次持有人会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 二、持有人会议审议情况 与会持有人逐项审议并通过了如下议案： （一）审议并通过《关于设立公司第一期员工持股计划管理委员会的议案》 为保证本次员工持股计划的顺利实施，保障持有人的合法权益，根据公司《第 一期员工持股计划》和公司《第一期员工持股计划管理办法》的相关规定，公司 拟设立本员工持股计划管理委员会，作为本员工持股计划的日常管理与监督机构， 代表持有人行使员工持股计划资产所对应的股东权利。员工持股计划管理委员会 由 3 名委员组成，设管理委员会主任 1 人，管理委员会委员的任期与本员工持股 计划的存续期一致。 表决结果：同意 113,173,500 份，占出席会议的持有人所持有表决权份额总 1本员工持股计划本次实际认购人数 268 人（不含预留份额），对应实际认购股份 3,135 万股，本次认购价 格为 3.61 元/股。本员工持股计划以"份"作为认购单位，每份份额为 ...

证券代码：002252 证券简称：上海莱士 上海莱士血液制品股份有限公司 投资者关系活动记录表 编号：2023-008 √特定对象调研 □分析师会议 投资者关系 □媒体采访 □业绩说明会 活动类别 □新闻发布会 □路演活动 □现场参观 □其他（请文字说明其他活动内容） 参与单位名称 华安证券股份有限公司 陈珈蔚 及人员姓名 时间 2023年 9月25日 15:00—16:30 地点 公司会议室 上市公司 刘 峥 副总经理、董事会秘书 接待人员姓名 褚忠君 市场总监 一、交流互动环节 问题 1：请介绍行业供需结构？ 回复：目前血液制品企业以生产人血白蛋白类、静注人免疫球蛋白类为 主，上述两类产品处于供需紧平衡状态。 ...

证券代码：002252 证券简称：上海莱士 公告编号：2023-068 上海莱士血液制品股份有限公司 关于第一期员工持股计划非交易过户完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"或"上海莱士"）于 2023 年 7 月 28 日分别召开了第五届董事会第二十六次（临时）会议和第五届监事会第十九 次会议，会议审议并通过了《关于<公司第一期员工持股计划（草案）>及其摘要 的议案》、《关于<公司第一期员工持股计划管理办法>的议案》等相关议案，同意 公司实施第一期员工持股计划（"本员工持股计划"）。上述议案已由 2023 年 8 月 16 日召开的 2023 年第二次临时股东大会审议通过，股东大会授权董事会办理与 本员工持股计划相关的事宜。具体内容详见公司在《证券时报》、《中国证券报》、 《上海证券报》、《证券日报》和巨潮资讯网（www.cninfo.com.cn）上披露的相关 公告。 一、本员工持股计划的股票来源及数量 本员工持股计划的股份来源为公司回购专用证券账户的上海莱士 A 股普通 股股份。 公司分别于 20 ...

证券代码:002252 证券简称:上海莱士 上海莱士血液制品股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------|---------------|-------------------------------| | | √特定对象调研 | □分析师会议 | | 投资者关系活动类别 | □媒体采访 □ | 业绩说明会 | | | □新闻发布会 □ | 路演活动 | | | □现场参观 | □其他(请文字说明其他活动内容) | 参与单位名称 及人员姓名 海通证券股份有限公司 彭娉 德邦基金管理有限公司 揭诗琪 时间 2023 年 9 月 14 日 14:00—16:00 地点 公司会议室 | --- | --- | --- | |----------------------|--------|----------------------| | 上市公司接待人员姓名 | 刘 峥 | 副总经理、董事会秘书 | | | 褚忠君 | 市场总监 | 一、交流互动环节 问题 1:请介绍公司的销售情况? 回复:公司所处血液制品行业,该行业景气度较高,公司整体销售 ...

证券代码：002252 证券简称：上海莱士 公告编号：2023-067 上海莱士血液制品股份有限公司 关于公司股份回购实施结果暨股份变动公告 本次公司回购股份资金来源为自有资金，回购价格均未超过股份回购方案约 定的回购价格上限，实际回购资金总额已超过回购方案中的回购资金总额下限， 且不超过回购资金总额上限，本次回购股份方案已实施完毕。本次股份回购的实 施符合公司回购方案及相关法律法规的要求。 二、回购股份实施情况与回购股份方案不存在差异的说明 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）于 2023 年 6 月 2 日召开了第五 届董事会第二十四次（临时）会议，审议通过了《关于回购公司股份方案的议案》， 同意公司使用自有资金以集中竞价交易方式从二级市场回购公司股份，用于依法 注销减少注册资本或实施股权激励/员工持股计划。本次回购股份的资金总额为 不低于人民币 5 亿元（含）且不超过人民币 10 亿元（含），回购股份的价格不超 过人民币 8.00 元/股（含），具体回购股份数量以回购方案实施完毕时实际回购的 股份数量为 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥3,900,625,795.05, representing an increase of 18.43% compared to ¥3,293,523,885.37 in the same period last year[13]. - The net profit attributable to shareholders of the listed company was ¥1,238,999,444.63, up 16.77% from ¥1,061,072,064.74 in the previous year[13]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥1,201,167,722.56, reflecting a 13.43% increase from ¥1,058,972,524.69 year-on-year[13]. - The net cash flow from operating activities was ¥1,433,444,222.02, which is an increase of 87.39% compared to ¥764,952,685.41 in the previous year[13]. - Basic earnings per share rose to ¥0.184, a 17.20% increase from ¥0.157 in the same period last year[13]. - Total assets at the end of the reporting period were ¥32,173,320,657.61, up 5.63% from ¥30,457,959,495.12 at the end of the previous year[13]. - Net assets attributable to shareholders of the listed company increased to ¥30,423,564,750.41, a rise of 5.57% from ¥28,818,712,462.60 at the end of the previous year[13]. - The weighted average return on net assets was 4.17%, an increase of 0.21 percentage points compared to 3.96% in the previous year[13]. Business Operations - The main business of the company is the production and sale of blood products, including human albumin and immunoglobulins, making it one of the largest blood product manufacturers in China[16]. - The company has a total of 7 product types produced by Shanghai Laishi, 4 by Zhengzhou Laishi, 9 by Tonglu Biology, and 4 by Zhejiang Haikang, indicating a diverse product portfolio[17]. - Human albumin is used for treating shock from blood loss and edema caused by liver cirrhosis, among other medical conditions[18]. - The company has established a "one-to-one" supply relationship with plasma collection stations to ensure a stable supply of healthy human plasma, which is the main raw material for blood products[20]. - The company has exclusive distribution rights for human albumin and blood screening products in mainland China through its subsidiary Tonglu Medicine[16]. - The company produces various immunoglobulin products for treating primary and secondary immunodeficiencies and autoimmune diseases[18]. - The company’s coagulation factor products are used for treating hemophilia and other coagulation disorders, highlighting its role in critical medical treatments[19]. Financial Management - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[3]. - The company has outlined potential risks and corresponding countermeasures in its management discussion and analysis section[3]. - The company reported a non-recurring profit of CNY 37,831,722.07 after accounting for various non-operating income and expenses, with a tax impact of CNY 6,760,298.66 and minority interest effect of CNY -35,805.99[14]. - The company has no other non-recurring profit items that meet the definition of non-recurring profit, indicating a focus on core business operations[15]. Market Strategy - The company has adjusted its marketing strategy to focus on the coagulation factor market, responding to intensified competition in the coagulation factor VIII segment[23]. - The company is actively pursuing overseas market opportunities through authorized distribution models[22]. - The marketing strategy includes a combination of direct sales, academic promotion, and government procurement to meet diverse customer needs[29]. Research and Development - Research and development expenses increased by 35.24% to ¥86,867,295.05, reflecting the company's commitment to enhancing project development[30]. - The company is focusing on the development of new clinical diagnostic solutions targeting specific treatment areas, including infectious diseases and autoimmune diseases[59]. - The company has invested 100 million RMB in R&D for new technologies aimed at improving blood product processing efficiency[78]. Environmental Compliance - Shanghai Raist reported significant compliance with environmental protection laws, adhering to 24 key regulations[69]. - The company is classified as a key pollutant discharge unit by environmental protection authorities[70]. - Shanghai Raist is committed to sustainable practices, following the Clean Production Promotion Law and Circular Economy Promotion Law[71]. - The company has implemented measures to manage hazardous waste in accordance with national regulations[72]. - Shanghai Raist is actively involved in environmental impact assessments for its projects, ensuring compliance with the Environmental Impact Assessment Law[73]. Shareholder Information - The company approved a share repurchase plan with a total fund of no less than RMB 500 million and no more than RMB 1 billion, with a maximum repurchase price of RMB 8.00 per share[131]. - The first share repurchase occurred on July 14, 2023, with 6,531,878 shares bought back, representing 0.0969% of the total share capital, at a total cost of approximately RMB 48.78 million[132]. - The company’s major shareholder, Kilibof, holds 26.20% of the shares, and if all nominated directors are elected, Kilibof will exceed half of the board members[130]. Legal and Regulatory Matters - The company has ongoing litigation involving a claim of RMB 197.02949 million related to a debt responsibility case against Shenzhen Xifeng, with the first-instance court supporting the company's claims[116]. - The company is involved in a lawsuit regarding the enforcement of a civil judgment, with the Guangdong High Court hearing the case on June 29, 2023[116]. - The company has not reported any penalties or rectification measures during the reporting period[115]. Financial Position - As of June 30, 2023, the company's total assets amounted to RMB 32,173,320,657.61, an increase from RMB 30,457,959,495.12 at the beginning of the year, representing a growth of approximately 5.63%[150]. - The company's cash and cash equivalents increased to RMB 4,549,733,439.50 from RMB 3,977,425,328.72, reflecting a rise of about 14.39%[150]. - The total liabilities of the company as of June 30, 2023, were RMB 1,756,283,201.02, up from RMB 1,644,618,113.59, marking an increase of approximately 6.77%[152]. - The company's equity attributable to shareholders increased to RMB 30,423,564,750.41 from RMB 28,818,712,462.60, representing a growth of about 5.57%[152].